Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people livin
Generali Investments CEE investicni spolecnost a.s. Purchases 4,797 Shares of Biogen Inc. $BIIB
04:30am, Saturday, 28'th Mar 2026
Generali Investments CEE investicni spolecnost a.s. lifted its position in Biogen Inc. (NASDAQ: BIIB) by 12.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities a
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
10:41am, Friday, 27'th Mar 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics
08:00am, Wednesday, 25'th Mar 2026
- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170)
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action
08:00am, Thursday, 19'th Mar 2026
BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of the certific
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, tak
Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript
01:22pm, Wednesday, 18'th Mar 2026
Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript
Biogen Inc. $BIIB Shares Sold by Dimensional Fund Advisors LP
04:16am, Thursday, 12'th Mar 2026
Dimensional Fund Advisors LP cut its stake in Biogen Inc. (NASDAQ: BIIB) by 6.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
Josh Brown: Biotech growth stocks immune to disruption risk
12:37pm, Wednesday, 11'th Mar 2026
Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC's Halftime Report this week about large-cap biotech: “These are growth stocks where you don't have to worry about disrupti
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
10:41am, Wednesday, 11'th Mar 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
08:00am, Wednesday, 11'th Mar 2026
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy
Biogen Inc. (BIIB) Presents at Leerink Global Healthcare Conference 2026 Transcript
03:30pm, Tuesday, 10'th Mar 2026
Biogen Inc. (BIIB) Presents at Leerink Global Healthcare Conference 2026 Transcript
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
07:30am, Thursday, 05'th Mar 2026
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
05:06pm, Wednesday, 04'th Mar 2026
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
